ArticleVeterinary ophthalmology2026
Intravitreal Cidofovir Injection for Refractory End-Stage Glaucoma and Vision Loss in Silicone Oil-Filled Eyes Following Retinal Reattachment Surgery in Dogs: Four Cases.
Article in Veterinary ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveTo describe the clinical outcome of intravitreal cidofovir injection for palliative management of refractory end-stage glaucoma and vision loss in silicone oil-filled eyes following retinal reattachment surgery in dogs. PROCEDURES: Medical records of dogs that underwent a single intravitreal cidofovir injection for pharmacologic ciliary body ablation were retrospectively reviewed. Data collected included clinical history, intraocular pressure (IOP), post-injection ocular comfort, complications, and follow-up duration.
resultsFour dogs (four eyes) were included. All treated eyes demonstrated a marked reduction in IOP at the first post-injection recheck (14-28 days after injection; post-injection IOP range: 3-7 mmHg). Adequate pain control was achieved in all dogs throughout the follow-up period (median follow-up: 306.5 days; range: 40-369 days). Progressive phthisis bulbi developed in one case at long-term follow-up, while the remaining eyes maintained acceptable globe integrity and cosmetic appearance. Moderate to severe post-injection ocular discharge, conjunctival hyperemia, and aqueous flare were observed in all cases and were manageable with routine topical therapy. All owners reported satisfaction with post-injection comfort and appearance.
conclusionsA single intravitreal cidofovir injection may represent a feasible palliative option for controlling intraocular pressure and ocular pain in silicone oil-filled eyes with refractory glaucoma when enucleation is declined. Further studies are needed to better characterize long-term safety and outcomes in this clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.